Arrest Imatinib or Dasatinib in CML patients with Deep Molecular Responses (AID MORE)

Trial Profile

Arrest Imatinib or Dasatinib in CML patients with Deep Molecular Responses (AID MORE)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Feb 2018

At a glance

  • Drugs Dasatinib (Primary) ; Imatinib
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms AID MORE
  • Most Recent Events

    • 07 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top